Product updates
New SKUs concentrate on solid tumours and autoimmune disease; every in-stock item ships immediately with purity data and ELISA binding validation.
SanjingBio's in-stock recombinant protein catalogue has expanded to more than 90 SKUs, with new products concentrated on core solid-tumour and autoimmune targets. In-stock products can move directly into molecular screening and validation without a custom-production wait.
Every in-stock product includes purity characterisation and ELISA binding validation. Product specifications and current availability are maintained in the live catalogue record.
Core instruments now number 13. The 300 kV cryo-EM will be used for epitope analysis and complex-structure confirmation, supporting antigen design and antibody screening on membrane proteins and other hard targets.
Jul 21, 2026
Deliveries span mammalian, insect, yeast, E. coli and cell-free systems, with hard targets such as multi-pass membrane proteins taking a growing share.
Jun 12, 2026
A review of MSLN expression, five oncogenic mechanisms and the ADC/bispecific/CAR landscape, with SanjingBio's human/cyno MSLN binding and internalisation data.
Apr 17, 2026
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
